AveXis Inc (NASDAQ:AVXS) VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $109.72, for a total value of $195,301.60. Following the completion of the transaction, the vice president now directly owns 1,780 shares in the company, valued at approximately $195,301.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Sukumar Nagendran also recently made the following trade(s):
- On Friday, December 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The shares were sold at an average price of $94.77, for a total transaction of $168,690.60.
- On Wednesday, November 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The stock was sold at an average price of $101.26, for a total transaction of $180,242.80.
Shares of AveXis Inc (AVXS) opened at $117.50 on Friday. The firm has a market cap of $3,720.14, a P/E ratio of -21.06 and a beta of 2.46. AveXis Inc has a 1 year low of $50.56 and a 1 year high of $119.00.
AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same quarter in the prior year, the company earned ($0.87) EPS. equities analysts anticipate that AveXis Inc will post -6.23 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on the stock. Royal Bank of Canada reiterated a “hold” rating and set a $92.00 target price on shares of AveXis in a report on Thursday, November 2nd. Canaccord Genuity started coverage on shares of AveXis in a report on Thursday, October 26th. They set a “hold” rating and a $110.00 target price for the company. Zacks Investment Research downgraded shares of AveXis from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. BidaskClub raised shares of AveXis from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Finally, Citigroup increased their price target on shares of AveXis from $100.00 to $116.00 and gave the stock a “buy” rating in a research note on Monday, October 2nd. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $111.67.
A number of hedge funds have recently modified their holdings of the stock. California Public Employees Retirement System purchased a new stake in AveXis in the third quarter worth approximately $570,000. Cubist Systematic Strategies LLC boosted its stake in shares of AveXis by 688.6% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after acquiring an additional 1,577 shares during the last quarter. Highbridge Capital Management LLC purchased a new position in shares of AveXis during the 3rd quarter worth $967,000. Perceptive Advisors LLC boosted its stake in shares of AveXis by 147.5% during the 3rd quarter. Perceptive Advisors LLC now owns 671,181 shares of the company’s stock worth $64,923,000 after acquiring an additional 400,000 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of AveXis by 52.2% during the 3rd quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock worth $99,363,000 after acquiring an additional 352,456 shares during the last quarter. Institutional investors own 92.88% of the company’s stock.
WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/13/sukumar-nagendran-sells-1780-shares-of-avexis-inc-avxs-stock.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.